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TNF-a Regulates Human Plasmacytoid Dendritic Cells by
Suppressing IFN-a Production and Enhancing T Cell
Activation
Antonios Psarras,*,†,‡ Agne Antanaviciute,x Adewonuola Alase,*,† Ian Carr,x
Miriam Wittmann,*,† Paul Emery,*,† George C. Tsokos,‡ and Edward M. Vital*,†
Human plasmacytoid dendritic cells (pDCs) play a vital role in modulating immune responses. They can produce massive amounts
of type I IFNs in response to nucleic acids via TLRs, but they are also known to possess weak Ag-presenting properties inducing
CD4+ T cell activation. Previous studies showed a cross-regulation between TNF-a and IFN-a, but many questions remain about
the effect of TNF-a in regulating human pDCs. In this study, we showed that TNF-a significantly inhibited the secretion of IFN-a
and TNF-a of TLR-stimulated pDCs. Instead, exogenous TNF-a promoted pDC maturation by upregulating costimulatory
molecules and chemokine receptors such as CD80, CD86, HLA-DR, and CCR7. Additionally, RNA sequencing analysis showed
that TNF-a inhibited IFN-a and TNF-a production by downregulating IRF7 and NF-kB pathways, while it promoted Ag
processing and presentation pathways as well as T cell activation and differentiation. Indeed, TNF-a–treated pDCs induced
in vitro higher CD4+ T cell proliferation and activation, enhancing the production of Th1 and Th17 cytokines. In conclusion,
TNF-a favors pDC maturation by switching their main role as IFN-a–producing cells to a more conventional dendritic cell
phenotype. The functional status of pDCs might therefore be strongly influenced by their overall inflammatory environment, and
TNF-a might regulate IFN-a–mediated aspects of a range of autoimmune and inflammatory diseases. The Journal of Immu-
nology, 2021, 206: 000–000.
H
uman plasmacytoid dendritic cells (pDCs) consist of a
distinct DC population that play a vital role in modu-
lating immune responses. A common DC progenitor in
the bone marrow can generate both pDCs and conventional DCs
(cDCs), but pDCs are unique in their ability to produce type I
IFNs in response to viral infection (1). Upon ligation of TLR7 and
TLR9 with exogenous or endogenous nucleic acids, pDCs can
secrete massive amounts of type I IFNs, predominantly IFN-a,
and other proinflammatory cytokines. These effects lead to acti-
vation in both innate and adaptive immune compartments such as
enhancement of NK cell cytotoxicity, effector CD4+ and CD8+
T cell responses, B cell differentiation into plasma cells, and Ab
production (2–7).
Apart from type I IFN production, other cytokines such as
TNF-a can also be produced by pDCs upon viral stimulation (3).
Early studies demonstrated that the production of IFN-a, IFN-b,
and TNF-a by virus-stimulated pDCs can act on an autocrine
fashion on the cells, affecting their survival and further differen-
tiation enhancing T cell–mediated antiviral immunity (3, 8). More
recent transcriptomic data demonstrated that influenza can result
in differentiation of pDCs into multiple subgroups with distinct
phenotypes and functional properties (9).
Although not as efficient as cDCs, pDCs express MHC class II
(MHC-II) molecules and are able to capture, process, and present
Ags to CD4+ T cells, inducing their activation (10, 11). Receptors
specifically found on pDCs such as BDCA-2 can play a role in Ag
internalization switching the T cell activation properties of the
cells (12, 13). TLR-activated pDCs have enhanced Ag-presenting
function and can promote Th1 and Th17 differentiation (14–16).
Despite their weaker Ag-presenting properties, pDCs can also cross-
present exogenous Ags to CD8+ T cells and therefore induce anti-
viral and antitumor responses (5, 17, 18). However, unstimulated
pDCs predominantly facilitate tolerogenic immune responses by
expressing IDO and promoting CD4+ T cell anergy and regula-
tory T cell differentiation (19–22).
As the main drivers of type I IFN responses, pDCs have been
implicated in many diseases, especially chronic viral infections,
cancer, and autoimmunity (23–26). Multiple regulatory surface
receptors (e.g., BDCA-2, ILT7, BST2, and NKp44) control the
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aberrant production of type I IFNs by TLR-activated pDCs (12,
27, 28). Cross-regulation of TNF-a and IFN-a appears to be
important in many immune-mediated diseases (29–31). Previous
work on pDCs generated in vitro from CD34+ hematopoietic
progenitors clearly demonstrated a cross-regulation between TNF-a
and type I IFNs (31). TNF-a was shown not only to inhibit the
in vitro generation of pDCs but also to downregulate influenza-
induced IFN-a production. In addition, neutralization of endoge-
nous TNF-a secreted by influenza-stimulated pDCs could lead to
partially sustained IFN-a production (31). However, the mechanism
defining how TNF-a regulates these changes in IFN production and
the effects of TNF on other pDC functions still remains less well
understood.
In this study, we investigated the regulatory role of TNF-a on the
phenotype and function of blood-purified human pDCs. We found
that TNF-a is a major cytokine produced alongside IFN-a by
TLR9- or TLR7-stimulated pDCs and that exogenous TNF-a
strongly inhibited both IFN-a and TNF-a production, an effect
which is predominantly TLR9 and less TLR7 mediated. Addi-
tionally, TNF-a induced a distinct transcriptomic profile in pDCs
by promoting pathways related to Ag processing and presentation as
well as enhancing the ability of pDCs to induce T cell proliferation,
activation, and differentiation toward Th1 and Th17 in vitro. Our
findings demonstrate that TNF-a is a major regulator of human
pDCs and can enhance their function by switching their main role
as IFN-a–producing cells to a more cDC phenotype.
Materials and Methods
Isolation of human cells
Human PBMCs were separated from whole blood by density gradient
centrifugation using Leucosep tubes (Greiner Bio-One). A pDC-enriched
population was isolated from PBMCs by negative selection using the Di-
amond pDC Isolation Kit II (Miltenyi Biotec). pDCs were further sorted
using an Ab to BDCA-4 (Miltenyi Biotec). Naive CD4+ T cells were
purified by negative selection using the Naive CD4+ T Cell Isolation Kit II
(Miltenyi Biotec). Cell sorting was carried out at the St. James Campus
Infrastructure and Facilities Cytometry and Imaging Facility of the Well-
come Trust Brenner Building of the University of Leeds, with a BD Influx
Six-Way Cell Sorter (BD Biosciences).
Cell cultures
Cells were cultured in RPMI medium 1640 with GlutaMAX supplement
(Thermo Fisher Scientific) containing 10% (vol/vol) FBS and 100 U/ml
penicillin/streptomycin. For cytokine production, cells were stimulated
with 2 mM class A CpG (ODN 2216; Miltenyi Biotec) or ORN R-2336
(Miltenyi Biotec). For pDC/T cell coculture, pre-enriched pDCs were
treated with 10 ng/ml recombinant human TNF-a (R&D Systems) for 24 h
and then washed twice to remove residual TNF-a before use in subsequent
culture. Untreated or TNF-a–treated pDCs were cultured with allogeneic
naive CD4+ T cells at 1:5 ratio for 5 d. For cytokine detection, cells were
cultured in the last 4 h with GolgiPlug (BD Biosciences). Cell proliferation
was measured using the CellTrace Violet Cell Proliferation kit (Thermo
Fisher Scientific), according to the manufacturer’s instructions.
Human TNF-a neutralization
Pre-enriched pDCs were stimulated with ODN 2216 (1 ng/ml) or ORN
R-2336 (1 ng/ml) in the presence or absence of human TNF-a Ab (R&D
Systems). After 24 h, the plates were centrifuged to collect the superna-
tants, and the cells were washed twice before restimulation for an addi-
tional 24 h. Supernatants collected at 24 and 48 h were analyzed by Human
IFN-a Platinum ELISA Kit (eBioscience), according to the manufacturer’s
protocol.
Flow cytometry
For cell surface staining, fluorochrome-conjugated mAbs against human
CD3, CD4, CD19, CD14, CD56, CD11c, HLA-DR, CD123, CD303,
CD317, CD80, CD85g, isotype controls (Miltenyi Biotec), CD304, CD69
(BioLegend), CD86, and CCR7 (BD Biosciences) were used. For intra-
cellular staining, cells were first stained for surface markers and then fixed
and permeabilized using Intracellular Fixation and Permeabilization Buffer
Set (eBioscience) before incubation with fluorochrome-conjugated mAbs
against human IFN-a and TNF-a (Miltenyi Biotec) or TNF-a, IFN-g, and
IL-17A (BioLegend). Flow cytometry was performed on LSRII (BD
Biosciences) and Cytoflex S (Beckman Coulter) cytometers, and the data
were analyzed using FACSDiva (BD Biosciences) and CytExpert (Beck-
man Coulter) software.
Measurement of Ag uptake
pDCs were isolated from PBMCs (Miltenyi Biotec) and were then cultured in
RPMI medium 1640 with GlutaMAX supplement (Thermo Fisher Scientific)
containing 10% (vol/vol) FBS and 100 U/ml penicillin/streptomycin in a 96-
well plate. Purified pDCs were cultured with or without 10 mg/ml DQ OVA
(Molecular Probes) in the presence or absence of 50 ng/ml TNF-a. After
18 h, the cells were collected and then washed twice before data were an-
alyzed using flow cytometry.
RNA sequencing data generation
RNA from sorted pDCs was extracted using PicoPure RNA Isolation Kit
(Thermo Fisher Scientific) and quantified using Qubit RNA HS Assay Kit
(Thermo Fisher Scientific). RNA libraries were made by using SMART-Seq
V4 Ultra Low Input RNA Kit (Takara Bio) and Nextera XT DNA Library
Preparation Kit (Illumina) for next-generation sequencing. Indexed se-
quencing libraries were pooled and sequenced on a single lane on HiSeq
3000 instrument as 151 bp paired-end reads. Pooled sequence data were
then demultiplexed using Illumina bcl2fastq software, allowing no mis-
matches in the read index sequences.
RNA sequencing data processing and analysis
Raw paired-end sequence data in Fastq format was initially analyzed using
FastQC software to identify potential issues with data quality. Cutadapt
software (32) was then used to remove poor quality bases (Phred quality
score ,20) and contaminating technical sequences from raw sequenced
reads. Contaminating technical sequences identified at the initial quality
control stage were as follows: CTGTCTCTTATA, next era transposase
sequence; GTATCAACGCAGAGTACT, SMART-Seq oligonucleotide se-
quence; and dT30, SMART-Seq 39 CDS primer II sequence.
Reads trimmed to fewer than 30 nt and orphaned mate-pair reads were
discarded to minimize alignment errors downstream.
Reads were aligned to human hg38 analysis set reference sequences,
obtained from University of California Santa Cruz (UCSC) database (33)
using splicing-aware STAR aligner (34) for RNA sequencing data. STAR
aligner was run in two-pass mode, with known splice junctions supplied in
gene transfer format file, obtained from hg38 RefSeq gene annotation table
from UCSC database using Table Browser tool (35). The resulting align-
ments in Binary Alignment Map file format were checked for quality using
QualiMap software (36) and Picard tools (37). Picard tools were used to
mark PCR/optical duplicate alignments. Custom code was used to filter out
contaminating rRNA alignments, using rRNA coordinates for hg38 anal-
ysis set reference obtained using UCSC Table Browser tool. The final
alignment files were sorted and indexed using Samtools software (38) and
visualized using Integrative Genomics Viewer browser (39).
Bioconductor R package RSubread (40) was used to extract raw se-
quenced fragment counts per transcript using RefSeq hg38 transcript an-
notation set, as before. Paired-end reads were counted as a single fragment,
and multimapping read pairs were counted as a fraction of all equivalent
alignments. Raw count data were normalized for library size differences
using median ratio method (41), as implemented in DESeq2 R Bio-
conductor package (42). DESeq2 was also used to perform additional data
quality control steps and differential expression analyses. Differentially
expressed gene (DEG) expression was visualized as clustered heat maps
using Pheatmap R package (43), using log-transformed normalized gene
expression values as input. Gene functional and pathway enrichment
analyses were performed using R Bioconductor packages clusterProfiler
(44) and ReactomePA (45). Additionally, Kyoto Encyclopedia of Genes
and Genomes (46) pathways were visualized using Pathview package (47).
RNA sequencing data are available in BioProject: https://www.ncbi.nlm.
nih.gov/bioproject, accession number PRJNA645253.
To confirm that the sorted cells were pDCs rather than AXL+SIGLEC6+
DCs (AS-DCs), we analyzed key transcripts associated with each cell type.
This confirmed a high expression of the pDC marker TCF4 and a low
expression of the AS-DC markers SIGLEC 1, 2, 3, and 6, KLF4, and AXL
(Supplemental Table III).
Statistical analysis
Statistical analyses were carried out with Prism software (GraphPad).
Continuous variables were compared using either Student t test or ANOVA
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followed by pairwise Tukey tests. Pearson correlation was used for
associations. A p value # 0.05 was considered significant. In all figures,
error bars indicate SEM unless stated otherwise: *p , 0.05, **p , 0.01,
***p , 0.001, and ****p , 0.0001.
Results
Human pDCs produce both IFN-a and TNF-a in response to
TLR9 and TLR7 agonists
Although pDCs are mostly recognized for their IFN-a–producing
capacity, they are also capable of producing other proinflammatory
cytokines. To evaluate this, peripheral blood pDCs were ana-
lyzed by flow cytometry for the production of both IFN-a and
TNF-a upon stimulation with TLR9 (ODN 2216) or TLR7 (ORN
R-2336) agonists. Circulating pDCs produced no IFN-a and/or
TNF-a without external stimulation (Fig. 1B). After external
stimulation with TLR9 agonist, three major populations of pDCs
could be observed: 1) nonproducers, 2) TNF-a producers, and 3)
IFN-a and TNF-a producers (Fig. 1C). Similar results could be
seen when the cells were also stimulated with TLR7 agonist
(Fig. 1D).
TNF-a regulates IFN-a and TNF-a production in
TLR-stimulated pDCs
To understand the role of TNF-a on pDC function, we first in-
vestigated the effect of TNF-a on cytokine production in the
presence or absence of TLR stimulation. Freshly isolated PBMCs
were cultured in the absence or presence of different concentra-
tions of recombinant human TNF-a (1–50 ng/ml) for 24 h. We
observed no induction of IFN-a and/or TNF-a production in TNF-
treated pDCs without exogenous stimulation (Fig. 2A). However,
treatment with TNF-a significantly inhibited pDCs’ production of
cytokines in response to TLR9 or TLR7 agonists. For TLR9
stimulation, exogenous TNF-a strongly inhibited both IFN-a
(Fig. 2B) and TNF-a (Fig. 2C) production by pDCs. For TLR7
stimulation, exogenous TNF-a had a similar effect on inhib-
iting IFN-a production (Fig. 2B), but a significant reduction
in TNF-a production was only seen at higher concentrations
(Fig. 2C).
We next investigated whether neutralization of endogenous
TNF-a had an impact on IFN-a production. We isolated a pDC-
enriched population from PBMCs by negative selection using
magnetic beads (purity .92%), and the cells were stimulated with
ODN 2216 or ORN R-2336 in the absence or presence of anti-
TNF Ab or isotype control. After 24 h, the supernatants were
collected, and IFN-a production was measured by ELISA
(Fig. 2D). The cells were then washed twice and restimulated with
ODN 2216 or ORN R-2336, and the supernatants were collected
after an additional 24 h. IFN-a production was measured by
ELISA (Fig. 2E). In the first culture (0–24 h), neither anti-TNF–
neutralizing Ab nor isotype control altered the levels of IFN-a
secreted. However, in the secondary culture (24–48 h), anti-TNF–
treated pDCs restimulated with ODN 2216 (TLR9 agonist) could
partially maintain IFN-a secretion in comparison with the control-
treated pDCs (p , 0.05). This effect could not be seen in pDCs
restimulated with ORN R-2336 (TLR7 agonist) as the levels of
IFN-a secreted were similar in both anti-TNF– and control-treated
pDCs.
RNA sequencing data generation
We sought to investigate how TNF-a regulates TLR-mediated
cytokine production and induces further transcriptional changes
in human pDCs. pDCs from healthy donors (n = 3) were purified
FIGURE 1. Human pDCs produce both IFN-a and TNF-a in response to TLR9 and TLR7 agonists. (A) Gating strategy for human pDCs; pDCs are
characterized by the lack of lineage markers (CD3, CD19, CD14, CD56, and CD11c), intermediate to high expression of MHC-II (HLA-DR), and high
expression of CD123 and CD303 (BDCA-2). Freshly isolated PBMCs were cultured and stimulated with TLR9 (ODN 2216) or TLR7 (ORN R-2336)
agonists for 6 h, and then IFN-a and TNF-a production was detected using intracellular staining. (B) Unstimulated pDCs produced no IFN-a and/or
TNF-a. (C and D) Upon stimulation with TLR9 or TLR7 agonists, there were three major pDC populations: 1) nonproducers, 2) TNF-a producers, 3)
IFN-a and TNF-a producers. Results shown are representative of three independent experiments.
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by negative selection using magnetic beads. The pre-enriched
pDCs (purity .85%) from each donor were divided into two al-
iquots before they were cultured in the presence or absence of
human recombinant TNF-a (10 ml/ml) for 18 h. After incubation,
untreated and TNF-treated pre-enriched pDCs from all three do-
nors (n = 6) were washed and sorted based on CD304 (BDCA-4)
expression to achieve purity .99%.
Principal component analysis demonstrated that the main source
of variation in each sample derived from the treatment with TNF-a
(Supplemental Fig. 1A). In total, the analysis indicated 1800
DEGs at ,5% false discovery rate between untreated and TNF-
treated pDCs. The top 100 upregulated and downregulated genes
by TNF-a in pDCs can be found in Supplemental Tables I and II,
respectively.
TNF-a promotes transcriptional changes associated with Ag
processing and presentation
TNF-a induced the upregulation of genes in pDCs, which were par-
ticularly enriched for pathways associated with MHC-II Ag processing
and presentation, Th17 differentiation, Th1 and Th2 differentiation,
FIGURE 2. TNF-a regulates IFN-a and TNF-a production in TLR-stimulated pDCs. (A) Freshly isolated PBMCs were cultured in the absence or
presence of recombinant human TNF-a. After 24 h, PMBCs were washed twice and stimulated with TLR9 (ODN 2216) or TLR7 (ORN R-2336) agonists
for 6 h, and then IFN-a and TNF-a production by pDCs was measured using intracellular staining. Results shown are representative of three independent
experiments. (B and C) PBMCs were cultured according to (A) with different concentrations of exogenous TNF-a (0–50 ng/ml). After TLR9 or TLR7
stimulation for 6 h, both IFN-a and TNF-a production by pDCs was measured using intracellular staining. (D) Purified pDCs were stimulated with TLR9 or
TLR7 agonists in the absence or presence of anti-TNF Ab or isotype control. After 24 h, the supernatants were collected, and IFN-a production was
measured by ELISA (0–24 h). (E) pDCs were washed twice and restimulated according to (D), and the supernatants were collected after an additional 24 h.
IFN-a production was measured by ELISA (24–48 h). Results shown are representative of three independent experiments. Bars represent median value with
95% confidence interval. *p , 0.05, **p , 0.01. ns, not significant.
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MHC class I Ag processing and cross-presentation, induction of
TCR signaling and costimulation of CD28, phosphorylation of
CD3 and TCR z-chains, and translocation of ZAP70 to immu-
nological synapse among other pathways. A detailed presenta-
tion of enriched Reactome and Kyoto Encyclopedia of Genes
and Genomes pathways in DEGs can be seen in Figs. 3A and
4A, respectively as well as Supplemental Fig. 1B. Among the
most enriched biological processes induced by TNF-a were
found to be lymphocyte aggregation, T cell activation, immune
response–activating cell surface receptor signaling, Ag process-
ing and presentation of exogenous Ag, and T cell costimulation.
Regarding the enriched cellular components in DEGs, these in-
cluded units and functions mainly related to Ag processing and
presentation (Supplemental Fig. 2A); for instance, endocytic vesicle
membrane, MHC-II protein complex, clathrin-coated vesicle mem-
brane, and others.
Among the upregulated genes in TNF-treated pDCs compared
with untreated pDCs were HLAs corresponding to MHC class I
FIGURE 3. TNF-a promotes transcriptional changes associated with Ag processing and presentation. (A) Enriched Reactome pathways in DEGs up-
regulated by TNF-a in pDCs compared with untreated pDCs. (B–D) Heat maps showing that TNF-a promotes *DEGs associated with Ag processing and
presentation, T cell proliferation, and T cell activation pathways in pDCs.
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(HLA-A, HLA-B, and HLA-F) as well as MHC-II (HLA-DPA1,
HLA-DPB1, HLAD-DRA, HLA-DRB1, HLA-DRB5, HLA-DQA1,
HLA-DQA2, HLA-DQB1, and HLA-DMB).
Analyzing the RNA sequencing data further for the biological
effects of TNF-a on the function of pDCs, DEGs associated with
positive regulation of T cell proliferation and activation were
particularly enriched (Fig. 3B). Upregulated genes included co-
stimulatory molecules (CD80, CD86, CD83), molecules pro-
moting endocytosis (CD59) and cell adhesion (ADAM8), ICOS
ligand (ICOSLG), and IL-27 subunit b (EBI3). In contrast,
downregulated genes included CCR2, PTPRC, SYK, IL1B,
LILRB2, and SOCS1, among others. TNF-a also upregulated
genes associated with T cell differentiation (RPL22, ADAM8,
IRF4, CD83, RELB, FAS, and SEMA4A), particularly toward
Th17, Th1, and Th2 pathways (Fig. 4B).
TNF-a inhibits the transcription of genes encoding members of
the TLR signaling cascade
Despite the transcriptional changes toward Ag processing and
presentation as well as T cell activation and differentiation, TNF-a
seemed to negatively regulate other functions of pDCs. Among the
downregulated genes in TNF-treated pDCs compared with
untreated pDCs, there were enriched pathways associated with
G protein–coupled receptor cascade signaling, TLR cascade
signaling and IFN-a/b secretion (MyD88 and MAPK signaling
pathways), phagosomal maturation (early endosomal stage),
FIGURE 4. TNF-a promotes transcriptional changes associated with T cell differentiation. (A) Enriched KEGG pathways in DEGs upregulated by TNF-a in
pDCs. (B–D) Heat maps showing that TNF-a promotes DEGs associated with T cell differentiation toward Th17, Th1, and Th2 pathways in pDCs.
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FIGURE 5. TNF-a inhibits TLR cascade signaling pathways. (A) Enriched Reactome pathways in DEGs downregulated by TNF-a in pDCs. (B) Heat
maps showing that TNF-a promotes DEGs associated with negative regulation of TLR cascade signaling pathway in pDCs. (C) DEGs in TNF-treated
versus untreated pDCs associated with negative regulation of TLR-mediated type I IFN production.
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and regulation of trafficking and processing of endosomal
TLRs (Fig. 5A, Supplemental Fig. 2B).
As type I IFN and proinflammatory cytokine production by pDCs
is primarily mediated by TLR7 and TLR9 ligation with nucleic
acids in early endosomes, the effect of TNF-a in TLR cascade
signaling was interrogated in the RNA sequencing data analysis.
Not surprisingly, since the in vitro experiments confirmed that
TNF-a inhibits the secretory function of pDCs, there was a sig-
nificant downregulation of genes encoding intracellular proteins
and kinases mediating the phosphorylation of IRF7, NF-kB, and
AP-1 with the eventual outcome of the production of type I IFNs
and proinflammatory cytokines (Fig. 5B). There was a statistically
significant reduction in the expression levels of TLR9, MyD88,
IRAK2, IRAK4, and IRF7. In contrast, there was upregulation of
FIGURE 6. TNF-a upregulates costimulatory molecules and maturation markers on pDCs. pDCs were purified from freshly isolated PBMCs and
cultured in the absence or presence of recombinant human TNF-a. After 24 h, pDCs were analyzed by flow cytometry. Fluorescence intensity is shown on
the x-axis. Results shown are representative of three independent experiments. (A) TNF-a upregulates HLA-DR (MHC-II), costimulatory molecules such as
CD80 and CD86, and CCR7 but downregulates pDC-specific markers such as BDCA-2 (CD303). TNF-a also upregulates receptors related to type I IFN
regulation such as ILT7 (CD85g) and CD317 (BST2; tetherin). Results shown are representative of three independent experiments.
FIGURE 7. TNF-a enhances Ag uptake and processing by pDCs. (A) pDCs were purified by freshly isolated PBMCs and cultured alone or with 10 mg/ml
DQ OVA in the presence or absence of 50 ng/ml TNF-a for 18 h. Ag uptake and processing was measured by flow cytometry based on mean fluorescence
intensity (MFI). One representative experiment is shown out of three independent experiments. (B) Summary of the DQ OVA uptake of untreated pDCs, DQ
OVA–treated pDCs, and DQ OVA/TNF–treated pDCs. Data are presented as means 6 SEM for three independent experiments. **p , 0.005.
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FIGURE 8. TNF-a–treated pDCs enhance T cell proliferation and activation. (A) Allogeneic naive CD4+ T cells were labeled with CellTrace Violet and
cultured alone or with pDCs or TNF-a–treated pDCs for 5 d. T cell proliferation was analyzed by flow cytometry based on CellTrace Violet dilution. One
representative experiment is shown out of three independent experiments. (B) Average percentage of proliferated CD4+ T cells cocultured with pDCs or
TNF-a–treated pDCs (n = 3). (C) Expression of CD69 on CD4+ T cells from the cultures shown in (A). One representative experiment is shown out of three
independent experiments. (D) Average expression of CD69 on CD4+ T cells cocultured with pDCs or TNF-a–treated pDCs (n = 3). (E–J) Allogeneic naive
CD4+ T cells were cultured alone or with pDCs or TNF-a–treated pDCs for 5 d. Percentage of TNF-a (E), IFN-g (G), (Figure legend continues)
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the NF-kB inhibitor (NFKBIA) known to block the translocation
of NF-kB to the nucleus (Fig. 5C). In addition, TNF-treated
pDCs presented a significant downregulation of common IFN-
stimulated genes, including SOCS, IFI30, IRF7, IFITM2, IFITM3,
and OAS1, whereas there was upregulation of other IFN-
stimulated genes such as BST2, IRF4, NUP62, and IFNGR2
(Supplemental Fig. 2C).
TNF-a upregulates maturation markers and costimulatory
molecules on pDCs
To validate the RNA sequencing data at protein level, purified
pDCs were cultured in the presence or absence of exogenous
TNF-a for 24 h before the expression of surface molecules was
then measured by flow cytometry (Fig. 6). TNF-a strongly
upregulated maturation markers such as HLA-DR (MHC-II)
and CCR7 (CD197) as well as the costimulatory molecules
CD80 and CD86 on pDCs. Molecules related to the negative
regulation of IFN-a such as ILT7 (CD85j) and CD317 (BST2,
tetherin) were also upregulated. In contrast, TNF-a downreg-
ulated pDC-specific markers such as BDCA-2 (CD303).
TNF-a enhances Ag uptake and processing by pDCs
Based on RNA sequencing data analysis, we further cultured pDCs
to assess whether TNF-a could enhance Ag uptake and pro-
cessing. First, pDCs were purified from freshly isolated PBMCs
as described above and were then cultured alone or with 10 mg/ml
DQ OVA in the presence or absence of 50 ng/ml TNF-a. After
18 h, pDCs were harvested, and DQ OVA processing was ana-
lyzed by flow cytometry based on the level of mean fluorescence
intensity. Almost all pDCs in the presence or absence of TNF-a
were able to internalize and process DQ OVA as compared with
the negative control (Fig. 7A). Interestingly, TNF-a significantly
enhanced the uptake of DQ OVA by pDCs demonstrating an
increased Ag processing capacity (Fig. 7B). These results con-
firmed that TNF-a favored Ag uptake and processing by human
pDCs.
TNF-a–treated pDCs enhance T cell proliferation
and activation
Following RNA sequencing data analysis, we performed a series of
in vitro allogeneic pDC–naive CD4+ T cell cocultures to evaluate
whether TNF-a could enhance the ability of pDCs to induce T cell
activation. First, pDCs were cultured in the presence or absence of
exogenous TNF-a (10 ng/ml) for 24 h. After washing thoroughly,
pDCs were cocultured with allogeneic naive CD4+ T cells for 5 d.
T cell proliferation was assessed based on CellTrace Violet dilu-
tion upon cell division using flow cytometry. Both sets of pDCs
could induce T cell proliferation without exogenous stimulation
(Fig. 8A). However, TNF-treated pDCs were more efficient as
they induced a significantly higher percentage of proliferating
T cells (Fig. 8B). Similarly, TNF-treated pDCs induced a higher
expression of CD69 on CD4+ T cells (Fig. 8C, 8D). Regarding
cytokine production, TNF-treated pDCs induced a notably higher
production of TNF-a (Fig. 8E, 8F, 2.39 versus 4.74%) and IFN-g
(Fig. 8G, 8H, 9.54 versus 13.05%) as well as IL-17A (Fig. 8I, 8J,
1.05 versus 2.08%) in comparison with untreated pDCs. Collec-
tively, these results confirmed that TNF-a enhances the capacity
of pDCs to induce T cell proliferation and activation favoring the
production of Th1 and Th17 cytokines.
Discussion
Apart from the major role of pDCs as type I IFN–producing cells,
pDCs are able to capture, process, and present Ags to CD4+
T cells. However, the regulation of these functions was previously
elusive. Previous studies reported the cross-regulation of TNF-a
and IFN-a during in vitro stimulation of pDCs with influenza
virus; however, the precise mechanism for this effect was not fully
addressed (31). It was also shown that TNF-a in combination with
IFN-a promotes induction of CD80 and CD86 on pDCs (3). In this
study, we demonstrated that TNF-a not only inhibited IFN-a
production even at minimal concentrations but also had a similar
regulatory effect on autologous TNF-a production, predominantly
in a TLR9-mediated manner.
Although we have elucidated the regulation of the well-
known pDC, it is important to consider other related DC
subsets more recently described. The traditional pDC pop-
ulation is characterized by the expression of genes associated
with pathogen sensing and induction of type I IFNs as well as
the master regulator transcription factor TCF4 (48). A novel
DC subset was previously described with a unique gene sig-
nature (AXL, SIGLEC6, SIGLEC1, and SIGLEC2) sharing
features of both cDCs and pDCs (“AS-DCs”) (49, 50). AS-DCs
are characterized by the expression of HLA-DR, CD34, and
BDCA-3 but, unlike pDCs, they demonstrate CD11c expres-
sion as cDCs (50, 51). In contrast, both the expression of
CD123 and BDCA-2 appears to be lower. In our data, RNA
sequencing analysis of sorted pDCs showed a high expression
of the main transcription factor defining pDC lineage TCF4
(E2-2) but no expression of the AS-DC markers SIGLEC-6
(CD33L), SIGLEC-1 (CD169), and SIGLEC-2 (CD22) and
very minimal expression of AXL and SIGLEC-3 (CD33). In
addition, TNF-a did not upregulate any of the AS-DC markers
but promoted Ag-presenting properties by different transcriptomic
changes.
Another single-cell RNA sequencing study revealed the diver-
sification of human pDCs in response to influenza virus into three
phenotypes (P1-, P2-, and P3-pDCs) with distinct transcriptional
profiles and functions (9). The P3-pDCs were identified by higher
expression of CD80, CD86, other costimulatory molecules, and
CCR7; they also had a high potency of activating T cells mainly
toward Th2 responses. We found that TNF-a can induce the up-
regulation of all costimulatory molecules on pDCs alongside
CCR7, favoring the activation of T cells mainly toward Th1 and
Th17 responses. Another novel pDC subset characterized as
CD2hiCD5+CD81+ was also shown to induce strong T and B cell
activation but not to be able to secrete type I IFNs (52). In our
study, RNA sequencing data of TNF-treated pDCs revealed a
downregulation of this pDC-specific gene signature associated
with pathogen sensing (IRF7, TLR9, SLC15A4, and PACSIN1) and
secretion (DERL3, LAMP5, and SCAMP5) as well as TCF4
alongside its binding targets (SLA2, PTCRA, and PTPRCAP).
Hence, TNF-a strongly influenced the transcriptional profile of
pDCs by downregulating their classical pathways and upregulat-
ing genes (e.g., LY86) mostly related to the cDC phenotype. Our
data suggest that TNF-a can alter intracellular pathways and may
interfere with phosphorylation of transcription factors such as
IRF7 and IkB involved in cytokine production and other known
functions of pDCs.
and IL-17A (I) production by CD4+ T cells was measured by intracellular staining. One representative experiment is shown out of three independent
experiments. Average percentage of TNF-a (F), IFN-g (H), and IL-17A (J) produced CD4+ T cells cocultured with pDCs or TNF-a–treated pDCs (n = 3).
*p , 0.05, **p , 0.001, ***p , 0.001.
10 TNF REGULATES HUMAN pDCs











Other cytokines such as IL-21 have been shown to have a
regulatory impact on the function of pDCs promoting the secretion
granzymeB, which impairs their capacity to induce T cell proliferation
(53). In contrast, we showed that TNF-a enhanced the immunogenic
properties of pDCs toward Ag processing and presentation and T cell
activation and proliferation. Regarding TNFR superfamily, TNF-a
downregulated TNFRSF1A (TNFR 1A; CD120a) but not TNFRSF1B
(TNFR 1B; CD120b) and TNFRSF6B (decoy receptor 3; TR6; M68),
whereas it upregulated TNFRSF4 (OX40; CD134), FAS (Fas receptor;
Apo-1; CD95), and CD40 (Bp50; CD40). Interestingly, TNF-a pro-
moted the downregulation of IFNAR1 and IFNAR2 and the upregu-
lation of IFNGR1 and IFNGR2, receptors for IFN-g. This may
suggest that changes in TNFR1 and TNFR2 receptor expression ac-
company the functional changes in pDCs that we observed. Although
TNFR1 can mediate apoptosis, such an effect did not appear con-
sistent with our results, with an increase in T cell activation by pDCs
after TNF exposure. Changes in receptor expression at a protein level
and studying their functional significance require further work. In
future work, we will also study what signaling mechanisms explain
the differential responses to TLR7 and TLR9 ligands.
Linking these data to human disease, anti-TNF treatment has
been associated with lupus-like symptoms as well as an induction
of IFN signature in peripheral blood (30, 31, 54, 55). The syno-
vium of rheumatoid arthritis patients was reported to contain
pDCs able to activate T cells more efficiently (56). TNF-a as one
of the main pathogenic cytokines driving synovial inflammation
may alter local pDC function enhancing Ag presentation and
promoting Th1 and Th17 cell differentiation. In addition, anti-
TNF treatment in patients with paradoxical psoriasis prolonged
type I IFN production by pDCs through inhibition of their matu-
ration (57).
In summary, our data elucidate the plasticity of pDC function
according to their inflammatory environment. Although pDCs
possess weak Ag-presenting properties, TNF-a can enhance these
functions by switching their main role as IFN-a–producing cells
to a more cDC phenotype. This cytokine therefore plays a key role
in modulating the functional status of pDCs and may regulate
IFN-a–mediated aspects of a range of autoimmune and inflam-
matory diseases.
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Supplemental Figure 1. All 1,800 differentially expressed genes (DEGs) at < 5% false discovery 
rate (FDR) between untreated and TNF-treated pDCs. Principal component analysis (PCA) shows 
that the main source of variation in the data derives from the treatment with TNF-α. 
  




Supplemental Figure 2. Heatmap showing the differentially expressed genes (DEGs) in TNF-treated 




A: All 1,800 differentially expressed genes (DEGs) at < 5% false discovery rate (FDR) between untreated 
and TNF-treated pDCs. Principal component analysis (PCA) shows that the main source of variation in the 
data derives from the treatment with TNF-α.
B: Heatmaps showing the differentially expressed genes (DEGs) in TNF-treated vs. untreated pDCs related 






Supplemental Figure 3. Enriched cellular components in differentially expressed genes (DEGs) 
upregulated by TNF-α in pDCs  
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Supplemental Figure 4. Heatmap showing the differentially expressed genes (DEGs) in TNF-treated 




Supplemental Figure 5. Heatmap of differentially expressed genes in TNF-treated vs. untreated 
associated with IFN signaling pathway. 
  Supplemental Figure 2.
A: Enriched cellular components in differentially expressed genes (DEGs) upregulated by TNF-α in pDCs
B: Heatmap showing the differentially expressed genes (DEGs) in TNF-treated vs. untreated pDCs related 
to negative regulation of MAPK kinase activity.




Supplemental Table 1. Top 100 genes upregulated by TNF-α in pDCs.
Supplemental Table 2. Top 100 genes downregulated by TNF-α in pDCs.
Supplemental Table 3. Gene expression of markers related to AS-DCs and pDCs in 
control and TNF-treated cells.
